FDA Panel Says Data Don't Show Naproxen Is Safer NSAID

By Sindhu Sundar (February 11, 2014, 7:27 PM EST) -- A U.S. Food and Drug Administration panel voted Tuesday that there is not enough scientific proof to support claims that naproxen, a painkiller sold as Aleve by drug giant Bayer Corp., is safer than other nonsteroidal anti-inflammatory drugs including ibuprofen.

The panel voted 16-9 that there is not enough data to show that naproxen poses lower heart health risks compared with other NSAIDs including ibuprofen, which rival drugmaker Pfizer Inc. markets as Advil, and aspirin. The vote came on the second day of a joint meeting between the agency's arthritis advisory committee and its drug safety and risk management advisory committee,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!